Peroxisome proliferator-activated receptor α activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat

2008 ◽  
Vol 26 (3) ◽  
pp. 468-477 ◽  
Author(s):  
Tina Banks ◽  
Adebayo Oyekan
Keyword(s):  
Angiotensin Ii ◽  
Peroxisome Proliferator ◽  
Hemodynamic Effects ◽  
Peroxisome Proliferator Activated Receptor ◽  
Angiotensin Type

scholarly journals Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-γ

Hypertension ◽  
2008 ◽  
Vol 51 (2) ◽  
pp. 259-266 ◽  
Author(s):  
Daniel Walcher ◽  
Katharina Hess ◽  
Philipp Heinz ◽  
Kerstin Petscher ◽  
Dusica Vasic ◽  
...  
Keyword(s):  
Peroxisome Proliferator ◽  
Lymphocyte Migration ◽  
Peroxisome Proliferator Activated Receptor ◽  
Angiotensin Type

Control of pain initiation by endogenous cannabinoids

2018 ◽  
Author(s):  
Andrea G. Hohmann
Keyword(s):  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Peripheral Mechanism ◽  
Antinociceptive Effects ◽  
The Central Nervous System ◽  
Cns Side Effects ◽  
Endogenous Cannabinoids ◽  
Redundant Functions

The landmark paper discussed in this chapter, published by Calignano et al. in 1998, focuses on the control of pain initiation by endogenous cannabinoids. In the paper, analgesic lipid mediators are shown to be present in peripheral paw tissue where they control the ability of pain signals to ascend to the central nervous system (CNS). Anandamide acts through a peripheral mechanism to suppress inflammatory pain via cannabinoid type 1 receptors. Palmitoylethanolamine, subsequently identified as an endogenous ligand for peroxisome proliferator-activated receptor-α‎, produces peripheral antinociceptive effects via a mechanism similar to that for the cannabinoid type 2 receptor. These lipids do not serve redundant functions and, in combination, produce synergistic antinociceptive effects. These observations suggested that drug-development efforts targeting peripheral control of pain may elucidate improved pharmacotherapies that lack the unwanted CNS side effects of current treatments.

scholarly journals Renal Angiotensin Type 2 Receptors Mediate Natriuresis Via Angiotensin III in the Angiotensin II Type 1 Receptor–Blocked Rat

Hypertension ◽  
2006 ◽  
Vol 47 (3) ◽  
pp. 537-544 ◽  
Author(s):  
Shetal H. Padia ◽  
Nancy L. Howell ◽  
Helmy M. Siragy ◽  
Robert M. Carey
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Iii ◽  
Angiotensin Type
Sign in / Sign up

Export Citation Format

Share Document